The Relationship Between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease and the Risk Involved.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study explores the risk factors for sarcopenia in patients with chronic kidney disease and the effects of sarcopenia on cardiovascular disease. Treatment of sarcopenia and cardiovascular complications provides a basis for improving the quality of life and survival of patients with chronic kidney disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Roles of Uremic Toxins in Uremic Sacropenia

NCT03060590

Sarcopenia

COMPLETED

Chronic Kidney Disease-related Sarcopenia With Poor Prognosis

NCT05353660

Chronic Kidney Diseases Sarcopenia

RECRUITING

Impact of Acute Kidney Injury on Sarcopenia and Frailty in Patients With Liver Cirrhosis

NCT05389280

Cirrhosis Kidney Injury Sarcopenia +1 more

UNKNOWN

Sarcopenia and Physical Performance in Hemodialysis Patients

NCT04669184

End Stage Kidney Disease

UNKNOWN

Screening and Assessing the Risk Factors and Complications of Chronic Kidney Disease

NCT03246191

Chronic Kidney Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sarcopeniais a syndrome characterized by the loss of skeletal muscle mass, muscle strength, and muscle dysfunction. The high incidence of sarcopenia in patients with chronic kidney disease (CKD) is strongly associated with poor quality of life, cardiovascular events, and increased all-cause mortality. At present, the cause of sarcopenia in patients with CKD is still unclear, and factors such as inflammation, malnutrition, and hormone metabolism disorders may affect the occurrence and development of sarcopenia. This topic explores the risk factors of sarcopenia in patients with chronic kidney disease and the correlation between sarcopenia and the risk of cardiovascular disease, and provides a basis for the prevention and treatment of sarcopenia and cardiovascular complications, with a view to improving the prognosis of CKD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia CKD Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sarcopenia

CKD patients with sarcopenia, meeting the following two criteria (1) male LTI (lean tissue index)\< 7.0 kg/m2, female LTI \< 5.7 kg/m2; (2) Male HGS)(handgrip strength \< 26 kg, female HGS \< 18 kg.

No interventions assigned to this group

non-sarcopenia

CKD patients with non-sarcopenia

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presented by the Nephrology Center during August 2019 and March 2021
* Age 18-75 years;
* Patients with CKD2 or above (eGFR≤60 ml/(min 1.73m2)

Exclusion Criteria

* There are contraindications to bioelectrical impedance spectroscopy (BIS) . examination, such as amputation, metal implants in the body, etc.;
* Complicated with other serious diseases, such as malignant tumors, cirrhosis, systemic infections, etc.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No